Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Comparative two-dimensional proteome analysis was used to identify proteins differentially expressed in multiple clinical normal and breast cancer tissues. One protein, the expression of which was elevated in invasive ductal and lobular breast carcinomas when compared with normal breast tissue, was arylamine N-acetyltransferase-1 (NAT-1), a Phase II drug-metabolizing enzyme. NAT-1 overexpression in clinical breast cancers was confirmed at the mRNA level and immunohistochemical analysis of NAT-1 in 108 breast cancer donors demonstrated a strong association of NAT-1 staining with estrogen receptor-positive tumors. Analysis of the effect of active NAT-1 overexpression in a normal luminal epithelial-derived cell line demonstrated enhanced growth properties and etoposide resistance relative to control cells. Thus, NAT-1 may not only play a role in the development of cancers through enhanced mutagenesis but may also contribute to the resistance of some cancers to cytotoxic drugs.

Type

Journal article

Journal

Mol Cancer Res

Publication Date

09/2003

Volume

1

Pages

826 - 835

Keywords

Arylamine N-Acetyltransferase, Breast, Breast Neoplasms, Cell Division, Cell Survival, Drug Resistance, Neoplasm, Etoposide, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Organ Specificity, Proteomics, RNA, Messenger, Tumor Cells, Cultured, Up-Regulation